Higher serum levels of soluble intracellular cell adhesion molecule-1 and soluble vascular cell adhesion molecule predict peripheral artery disease in haemodialysis patients
Version of Record online: 29 OCT 2012
© 2012 The Authors. Nephrology © 2012 Asian Pacific Society of Nephrology
Volume 17, Issue 8, pages 718–724, November 2012
How to Cite
CHENG, C.-H., CHEN, Y.-S., SHU, K.-H., CHANG, H.-R. and CHOU, M.-C. (2012), Higher serum levels of soluble intracellular cell adhesion molecule-1 and soluble vascular cell adhesion molecule predict peripheral artery disease in haemodialysis patients. Nephrology, 17: 718–724. doi: 10.1111/j.1440-1797.2012.01654.x
- Issue online: 29 OCT 2012
- Version of Record online: 29 OCT 2012
- Accepted manuscript online: 21 AUG 2012 02:56AM EST
- Accepted for publication 14 August 2012.; Accepted manuscript online 21 August 2012.
- peripheral artery disease;
- soluble intracellular cell adhesion molecular-1;
- soluble vascular cell adhesion molecule-1
Aim: Serum levels of soluble intracellular cell adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM) and monocyte chemotactic protein 1 (MCP-1), are elevated in patients with peripheral artery disease (PAD). However, the levels of these cell adhesion molecules in patients undergoing haemodialysis (HD) are unclear.
Method: A total of 112 HD patients were included and PAD was diagnosed using the ankle-brachial index and Doppler ultrasound. Serum levels of sICAM-1, sVCAM-1 and MCP-1 were assayed using enzyme linked immunosorbent assay.
Results: Out of 106 HD patients, 31 (27.7%) were diagnosed with PAD. After adjusting for risk factors, higher serum levels of sVCAM-1 and sICAM-1 were associated with PAD in HD patients, with an odds ratio of 5.3 (95% CI 3.3–65.5) and 2.7 (95% CI 1.2–21.8) respectively. Using sVCAM-1 and sICAM-1 for diagnosis of PAD in HD patients, sVCAM-1 had a sensitivity of 72.4% and specificity of 62.3% for sVCAM-1 and sICAM-1 had a sensitivity of 89.3% and a specificity of 40%. MCP-1 was not associated with PAD in HD patients. In addition, the fistula of HD patients with PAD had a lower A-V access flow.
Conclusion: sVCAM-1 and sICAM-1 was associated with higher risk of PAD in HD patients. Moreover, HD patients with PAD had a lower blood flow and lower A-V access flow. Our results showed that sVCAM-1 and sICAM-1 may be used as screening markers for PAD in HD patients.